Related Experiment Video
Updated: Oct 26, 2025
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
3.6K
Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin
RuiJun Chen1,2, Marc A Suchard3,4, Harlan M Krumholz5,6
1Department of Biomedical Informatics, Columbia University Irving Medical Center, New York (R.C., P.B.R., G.H.).
Hypertension (Dallas, Tex. : 1979)
|July 26, 2021
Summary
This study investigated the impact of [keyword 1] on [keyword 2]. Our findings indicate a significant correlation, suggesting [keyword 3] implications.
Area of Science:
- Biomedical Research
- Genetics
Background:
- The role of [specific gene/protein] in [disease/process] remains incompletely understood.
- Existing research has yielded conflicting results regarding [specific factor].
Purpose of the Study:
- To elucidate the precise mechanism by which [specific gene/protein] influences [disease/process].
- To identify potential therapeutic targets within the [pathway name] pathway.
Main Methods:
- Utilized CRISPR-Cas9 gene editing in [cell line/organism] models.
- Performed quantitative real-time polymerase chain reaction (qRT-PCR) and Western blotting.
- Analyzed data using [statistical method].
Main Results:
- Demonstrated a significant upregulation of [specific gene/protein] in [condition].
- Observed a dose-dependent effect of [intervention] on [outcome measure].
- Identified [novel finding] as a key mediator.
Conclusions:
- The findings highlight [specific gene/protein] as a critical regulator of [disease/process].
- Suggests that targeting the [pathway name] pathway may offer a novel therapeutic strategy.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
603
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
603
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
1.8K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
1.8K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
943
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
943
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
1.9K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
1.9K
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
939
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
939
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
823
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
823